[Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review]

Infez Med. 2013 Mar;21(1):40-44.
[Article in Italian]

Abstract

Sarcoidosis is a chronic inflammatory multisystem disease of unknown aetiology. IFN-alfa is an immunomodulatory cytokine, currently used with ribavirin in the treatment of chronic hepatitis C infection. Due to its effects on the immune system, IFN-? may lead to the induction or exacerbation of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and sarcoidosis. We report on a 37-year-old man, presenting with sarcoidosis during a six-month course of PEG-IFN alfa-2a and ribavirin for chronic hepatitis C virus genotype 3 infection.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects*
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / immunology*
  • Male
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / adverse effects*
  • Prednisone / therapeutic use
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / immunology
  • Ribavirin / administration & dosage
  • Ribavirin / adverse effects*
  • Sarcoidosis / chemically induced
  • Sarcoidosis / diagnosis
  • Sarcoidosis / drug therapy
  • Sarcoidosis / immunology*

Substances

  • Antiviral Agents
  • Glucocorticoids
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a
  • Prednisone